Date Document
14/12/2018 Change of Director's Interest Notice
07/12/2018 Change of Director's Interest Notice
06/12/2018 ZLD to Invest in Development of Oral Spray Formulations
06/12/2018 SUD: SUDA Enters Agreement To Develop Cannabinoid Spray
30/11/2018 Results of Meeting
30/11/2018 Annual General Meeting Presentation 2018
27/11/2018 Investor Presentation - Non-deal Roadshow
26/11/2018 Opioid reduction clinical trial with St Vincent's Hospital
22/11/2018 Appendix 3B
14/11/2018 Correction to Unlisted Option Expiry Date
07/11/2018 Release From Escrow and Founders Commitment Not to Sell
31/10/2018 Appendix 4C - quarterly
31/10/2018 September 2018 Quarterly Report
29/10/2018 Notice of Annual General Meeting
12/10/2018 Managing Director Remuneration Variation
11/10/2018 Zelda Focuses Clinical Trial Activity
10/10/2018 US Autism Observational Study Underway
26/09/2018 First Patient Dosed in Zelda Insomnia Trial
25/09/2018 Investor Presentation - Non-deal Roadshow
04/09/2018 Zelda Forms New Partnership to Access German Market
31/08/2018 Appendix 4G
31/08/2018 Appendix 4E & Financial Statements
22/08/2018 Appendix 3B
22/08/2018 Two Key Clinical Appointments to Medical Advisory Board
30/07/2018 June 2018 Quarterly Report
30/07/2018 Appendix 4C - quarterly
16/07/2018 Initial Director's Interest Notice
16/07/2018 Commencement of New Managing Director
06/06/2018 Paediatric Brain Cancer Research Update
25/05/2018 Details of Company Address
22/05/2018 Appointment of Managing Director
30/04/2018 March 2018 Quarterly Report
30/04/2018 Appendix 4C - quarterly
23/04/2018 Insomnia Clinical Trial Update-Patient Recruitment Completed
18/04/2018 Research into Cannabinoids and Diabetes-Related Conditions
13/04/2018 US Autism Observational Study Receives IRB Approval
06/03/2018 Expansion of Pancreatic Cancer Research Programme
27/02/2018 Appendix 4D & FY18 Interim Financial Report
31/01/2018 December 2017 Quarterly Report
31/01/2018 Appendix 4C - quarterly
22/01/2018 Shares Begin Trading in the USA on the OTCQB Venture Market
12/01/2018 Appendix 3B
10/01/2018 Cancellation of Unlisted Options